Kymera Therapeutics (KYMR) Tops Q2 EPS by 10c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.62), $0.10 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $65 million versus the consensus estimate of $30.92 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• FTC files amicus brief challenging Amgen's Enbrel patent acquisition